Accreditation Information


The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement


ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UANs , 0022-0000-17-001-L01-P, 0022-0000-17-002-L01-P, 0022-0000-17-003-L01-P, 0022-0000-17-004-L01-P, 0022-0000-17-005-L01-P, 0022-0000-17-006-L01-P, 0022-0000-17-007-L01-P, 0022-0000-17-008-L01-P, 0022-0000-17-009-L01-P, 0022-0000-17-010-L01-P, and 0022-0000-17-011-L01-P and will award 5.75 contact hours (0.575 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes signing in at registration, attending the entire session for which credit is claimed, completing the activity evaluation and requesting credit online at conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.


The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This educational activity is offered for a maximum of 5.75 ANCC contact hours.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well.  ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 6.9 KBN contact hours. Provider #: 3-0008-01-18-864. In order to receive credit, participants complete CNE activity, complete the evaluation form.  Certificates may be printed once the evaluation is completed.

Needs Statement

The technology enabling precision medicine has been recently developed, however clinical application is lagging behind. Most clinicians have not been trained to interpret genetic tests or use them to guide patient therapy. Other barriers include difficulty in navigating the payer structures and lack of consensus on appropriate therapies for particular mutations.  


Upon completion of the activity, participants will be able to:

  1. Discuss precision medicine and its implications for clinical practice at UK
  2. Describe cancer disparities unique to Appalachian Kentucky
  3. Explain the population health implications of precision medicine initiatives
  4. Outline the significant opportunities genomic testing offers for more precise cancer treatment
  5. Assess the technical complexities of genomic testing and how this constrains the opportunities
  6. Outline the structure and process of molecular tumor boards
  7. Discuss the advantages and disadvantages of molecular tumor boards for guiding precision medicine treatment decisions
  8. Indicate patient specific genomic profiles to guide drug development and clinical trials
  9. Restate clinical trial options for cancer patients using precision medicine
  10. Identify patients who should be referred to a germline genetic clinic based on tumor testing results
  11. Explore potential challenges associated with incidental germline findings
  12. Assess the appropriateness of patients for presentation to a molecular tumor board
  13. Determine clinical implementation strategies of patient specific molecular tumor board recommendations
  14. Recognize the next-generation sequencing-based approach to identify driver mutations for targeted therapy
  15. Identify type of samples required for molecular profiling
  16. Describe the challenges to cover costs of precision medicine initiatives
  17. Recognize what payers (e.g., Medicare, Medicaid, private insurance) are willing to cover for precision medicine services
  18. Identify strategies to obtain third party reimbursement for off label use of targeted therapies
  19. Discuss strategies to obtain third party reimbursement for next generation sequencing testing in the clinical laboratory
  20. Identify required components of a clinical precision medicine strategy
  21. Describe promise and challenges in the clinical implementation of precision medicine
  22. Discuss how community oncologists, pathologists and others involved with cancer patients can participate in precision medicine and molecular tumor boards
  23. Identify successful strategies for community-academic partnerships for Molecular Tumor Boards
  24. Describe opportunities and challenges of community-academic partnerships around a molecular tumor board  

Target Audience

Oncologists, hematologists, pathologists, oncology nurses, researchers, pharmacists, genetic counselors, radiologists, cancer center administrators and cancer program are encouraged to attend.

Faculty Disclosure

All planners, speakers, authors, and reviewers involved with content development for continuing education activities provided by the University of Kentucky are expected to disclose any real or perceived conflict of interest related to the content of the activity. Detailed disclosures will be included in participant materials or given prior to the start of the activity.